Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New hope for ovarian cancer: targeted drug R-DXd enters key trial

NCT ID NCT06161025

Disease control Sponsor: Daiichi Sankyo Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Jul 29, 2026 · Updated 6 times

Summary

This study tests a new drug called raludotatug deruxtecan (R-DXd) in people with ovarian, peritoneal, or fallopian tube cancer that no longer responds to platinum chemotherapy. The drug is designed to target and kill cancer cells while sparing healthy ones. About 860 participants will be randomly assigned to receive R-DXd or standard chemotherapy. Researchers will measure how well the drug shrinks tumors and delays cancer growth.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Raludotatug deruxtecan (R-DXd), a targeted antibody-drug conjugate
What this could lead to
If successful, this could offer a new treatment option for people with ovarian cancer that has stopped responding to platinum-based chemotherapy.
What could go wrong
This is an early-to-mid stage trial, so the drug may not work better than current options or could have unexpected side effects. Results are not guaranteed.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2/3

Runs two stages together: whether the treatment works, then large-scale confirmation.

Participants

About 860 people

The number the study aims to enrol. It can still change while the study runs.

Started

Feb 2024

Expected to finish

Apr 2030

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Sign and date the informed consent form prior to the start of any study-specific qualification procedures. * Age ≥18 years or the minimum legal adult age (whichever is greater) at the time the informed consent form is signed. * Participants with histologically or cytologically documented high-grade serous ovarian cancer (OVC), high-grade endometrioid OVC, primary peritoneal cancer, or fallopian tube cancer. * For Phase 2 (Part A) Participants must have at least 1 lesion, not previously irradiated, amenable to biopsy, and must consent to provide a pretreatment biopsy and on-treatment biopsy tissue sample (on-treatment biopsy sample not required for the Phase 3 part of the study). Fresh pretreatment biopsy may be waived for subjects who consent to provide an archival tumor tissue sample from a lesion not previously irradiated, performed within 6 months of consent and performed after treatment with their most recent cancer therapy regimen. * For Phase 2 (Part A): Has received at least 1 but no more than 3 prior systemic lines of anticancer therapy. For Phase 3 (Part B): Has received at least 1 but no more than 4 prior systemic lines of anticancer therapy: * Neoadjuvant +/-adjuvant considered 1 line of therapy. * Maintenance therapy (eg, bevacizumab, poly-ADP ribose polymerase \[PARP\] inhibitors) will be considered part of the preceding line of therapy. * Therapy changed due to toxicity in the absence of progression will be considered part of the same line. * Hormonal therapy will be counted as a separate line of therapy, unless it was given as maintenance. * At least 1 line of therapy containing bevacizumab, unless the subject is not eligible for treatment with bevacizumab due to precautions/intolerance. Note: Subjects must have progressed radiologically on or after their most recent line of systemic therapy. Biochemical progression will not be considered progression for this study. * Has platinum-resistant disease. If a subject had only 1 line of platinum therapy, must have received at least 4 cycles of platinum, must have had a best response of not PD, and then progressed between \>90 and ≤180 days after the date of the last dose of platinum If a subject had 2 or 4 lines of platinum therapy, must have received at least 2 cycles of platinum and have progressed on or within 180 days after the date of the last dose of platinum. * If mirvetuximab soravtansine (MIRV) is locally available: Has had prior treatment with MIRV for participants with documented high-folate receptor alpha expression, unless the participant is not eligible for treatment with mirvetuximab soravtansine due to precautions/intolerance, or if the treatment is not approved or available locally. * Has at least 1 measurable lesion evaluated by computed tomography or magnetic resonance imaging according to Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1) per investigator assessment. * Eastern Cooperative Oncology Group performance status of 0 or 1. * Has adequate organ and bone marrow function as assessed by local laboratory (within 14 days before start of study drug administration). * Is willing and able to comply with scheduled visits, drug administration plan, laboratory tests, other study procedures and study restrictions. * For Phase 3 (Part B) only: Subjects must be eligible for one of the treatments included in the investigator's choice of chemotherapy arm. Exclusion Criteria * Has clear cell, mucinous, or sarcomatous histology, mixed tumors containing any histology, or low-grade/borderline OVC. (Note for Phase 3 \[Part B\]: seromucinous, low-grade serous carcinoma or ovarian sarcoma, carcinosarcoma and undifferentiated carcinoma are excluded.) * Inadequate washout period before Cycle 1 Day 1, defined as follows: * Major surgery \<28 days * Radiation therapy \<28 days (if palliative stereotactic radiation therapy without abdominal radiation, ≤14 days) * Systemic anticancer therapy (including antibody-drug therapy, retinoid therapy, and hormonal therapy) \<28 days or 5 half-lives, whichever is shorter, before starting study drug * Chloroquine/hydroxychloroquine \<14 days * Exposure to another investigational drug within 28 days prior to start of study treatment or current participation in other therapeutic investigational procedures * Clinically active brain metastases, spinal cord compression, or leptomeningeal carcinomatosis, defined as untreated or symptomatic, or requiring therapy with steroids or anticonvulsants to control associated symptoms. Subjects with untreated and asymptomatic brain metastases or subjects with treated brain metastases who are no longer symptomatic and who require no treatment with steroids may be included in the study if they have recovered from the acute toxic effect of radiotherapy, at the investigator's discretion A minimum of 2 weeks must have elapsed between the end of radiotherapy and randomization and there should be no evidence of progression or need for steroid treatment or anticonvulsants for at least 2 weeks prior to randomization. Note: If there is a history or suspicion of central nervous system. Note: If there is a history or suspicion of central nervous system metastasis, a CT scan of the head or MRI of the brain must be performed at baseline. * Any of the following within the past 6 months prior to randomization: cerebrovascular accident, transient ischemic attack, or other arterial thromboembolic event. * Uncontrolled or significant cardiovascular disease, including the following: * QT interval corrected with Fridericia's formula interval \>470 ms. * Diagnosed or suspected long QT syndrome. * History of clinically relevant ventricular arrhythmias, such as ventricular tachycardia, ventricular fibrillation, or Torsade de Pointes. * The participant has bradycardia of less than 50 bpm, unless the subject has a pacemaker. * History of second- or third-degree heart block. Candidates with a history of heart block may be eligible if they currently have pacemakers and have no history of fainting or clinically relevant arrhythmia with pacemakers. * Myocardial infarction within 6 months prior to screening. * Uncontrolled angina pectoris within 6 months prior to screening. * New York Heart Association Class 3 or 4 congestive heart failure. * Left ventricular ejection fraction \<50% or institutional lower limit of normal as measured by echocardiography or multigated acquisition (MUGA) scan. * Coronary/peripheral artery bypass graft within 6 months prior to screening * Uncontrolled hypertension (HgCTCAE Grade ≥3 hypertension as per NCI-CTCAE version 5.0). * Complete left or right bundle branch block. * Has a history of (noninfectious) ILD/pneumonitis that required corticosteroids, has current ILD/pneumonitis, or where suspected ILD/pneumonitis cannot be ruled out by imaging at screening. * Clinically severe pulmonary compromise resulting from intercurrent pulmonary illnesses including, but not limited to, any underlying pulmonary disorder (ie, pulmonary emboli within 3 months of the study enrollment, severe asthma, severe chronic obstructive pulmonary disease (COPD), restrictive lung disease, pleural effusion, etc) and any autoimmune, connective tissue, or inflammatory disorders with potential pulmonary involvement (eg, rheumatoid arthritis, Sjogren's syndrome, sarcoidosis, etc), or prior pneumonectomy. * Chronic steroid treatment (\>10 mg/day), with the exception of the following: * Inhaled steroids for asthma or COPD * Mineralocorticoids (eg, fludrocortisone) for subjects with orthostatic hypotension * Topical steroids for mild skin conditions * Low-dose supplemental corticosteroids for adrenocortical insufficiency * Premedication for treatment groups and/or premedication in case of any hypersensitivity * Intra-articular steroid injections * History of malignancy other than epithelial OVC, primary peritoneal cancer, or fallopian tube cancer within 3 years prior to enrollment, with the exception of those with a negligible risk of metastasis or death (eg, 5-year OS rate \>90%) and treated with expected curative outcome (such as adequately treated carcinoma in situ of the cervix, nonmelanoma skin carcinoma, ductal carcinoma in situ, or Stage 1 uterine cancer). * Unresolved toxicities from previous anticancer therapy, defined as toxicities (other than alopecia) not yet resolved to NCI-CTCAE Version 5.0, Grade ≤1 or baseline. Note: Subjects may be enrolled with chronic, stable Grade 2 toxicities (defined as no worsening to Grade \>2 for 3 months prior to randomization and managed with SOC treatment) that the investigator deems related to previous anticancer therapy, following discussion with the Sponsor, such as the following: * Chemotherapy-induced neuropathy * Fatigue * Endocrinopathies, which may include hypothyroidism, hyperthyroidism, Type 1 diabetes, hyperglycemia, and adrenal insufficiency * Skin pigmentation (vitiligo) * For Phase 2 (Part A): Prior exposure to other CDH6-targeted agents or an ADC that consists of an exatecan derivative that is a topoisomerase I inhibitor (eg, trastuzumab deruxtecan or datopotamab deruxtecan). For Phase 3 (Part B): Prior exposure to other CDH6-targeted agents or an antibody-drug conjugate containing a topoisomerase I inhibitor. * History of hypersensitivity to any excipients in the R-DXd or any known contraindication to treatment with, including hypersensitivity to, the study drug(s). * Has an active or uncontrolled human immunodeficiency virus (HIV) infection. * Has any evidence of severe or uncontrolled systemic diseases (including active bleeding diatheses or active infection, substance abuse) or other factors that, in the investigator's opinion, makes it undesirable for the subject to participate in the study or which would jeopardize compliance with the protocol. Screening for chronic conditions is not required. * Has an active or uncontrolled hepatitis B virus (HBV) or hepatitis C virus (HCV) infection. Hepatitis B and Hepatitis C Screening tests are required. Subjects are eligible if: 1. Hepatitis B virus surface antigen (HBsAg) positive are eligible if they have received HBV antiviral therapy for at least 4 weeks and have undetectable HBV viral load prior to randomization. 2. History of hepatitis C infection: eligible if the HCV viral load is below the level of detection in the absence of antiviral therapy during the previous 4 weeks. 3. Have normal transaminase values, or, if liver metastases are present, abnormal transaminases with a result of AST/ALT \<3 × ULN, which are not attributable to HCV infection. * Female who is pregnant or breastfeeding or intends to become pregnant during the study. * Psychological, social, familial, or geographical factors that would prevent regular follow-up. * Prior or ongoing clinically relevant illness, medical condition, surgical history, physical finding, or laboratory abnormality that, in the investigator's opinion, could affect the safety of the subject; alter the absorption, distribution, metabolism, or excretion of the study drug; or confound the assessment of study results. * Has a history of receiving live-attenuated vaccine (messenger RNA \[mRNA\] and replication-deficient adenoviral vaccines are not considered attenuated live vaccines) within 30 days prior to the first exposure to study intervention. * For Phase 3 (Part B) only: Has clinical symptoms or radiographic evidence of intestinal obstruction. * For Phase 3 (Part B) only: Has ascites or pleural effusions that require repeated drainage (less than 4 weeks between drainages).

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Platinum-resistant fallopian tube cancer are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

cancer fallopian tube cancer fallopian tube neoplasm ovarian cancer ovarian endometrioid adenocarcinoma ovarian serous adenocarcinoma primary peritoneal carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Solid cancer

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The study's own enquiry address

    This study publishes an address for enquiries. See it below .

  2. The places running it

    26 sites in 2 countries. The list below names each one and where it is.

  3. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  4. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Study contacts

  • Contact

    Email: •••••@•••••

Locations

  • Aichi Cancer Center Hospital

    ACTIVE_NOT_RECRUITING

    Nagoya, 464-8681, Japan

  • Alaska Women's Cancer Care

    RECRUITING

    Anchorage, Alaska, 99508, United States

  • Aretaieio Hospital

    ACTIVE_NOT_RECRUITING

    Athens, 11528, Greece

  • Arthur J. E. Child Comp CC

    ACTIVE_NOT_RECRUITING

    Calgary, Alberta, T2N 5G2, Canada

  • Asan Medical Center

    ACTIVE_NOT_RECRUITING

    Seoul, 05505, South Korea

  • Azienda Ospedaliera Per Lemergenza Cannizzaro

    ACTIVE_NOT_RECRUITING

    Catania, 95126, Italy

  • Azienda Ospedaliera Universitaria Careggi

    ACTIVE_NOT_RECRUITING

    Florence, 50134, Italy

  • Azienda Ospedaliera Universitaria Policlinico Sant'Orsola Malpighi IRCCS

    ACTIVE_NOT_RECRUITING

    Bologna, 40138, Italy

  • Baskent University Adana Application and Research Center

    ACTIVE_NOT_RECRUITING

    Adana, 01240, Turkey (Türkiye)

  • Baystate Medical Center

    ACTIVE_NOT_RECRUITING

    Springfield, Massachusetts, 01199-1001, United States

  • Beatson West of Scotland Cancer Centre

    ACTIVE_NOT_RECRUITING

    Glasgow, G12 0YN, United Kingdom

  • Beijing Cancer Hospital

    ACTIVE_NOT_RECRUITING

    Beijing, 100142, China

  • CARIO - Centre Armoricain de Radiothérapie, Imagerie médicale et Oncologie

    ACTIVE_NOT_RECRUITING

    Plérin, 22190, France

  • CHA Bundang Medical Center, CHA University

    ACTIVE_NOT_RECRUITING

    Seongnam-si, 13496, South Korea

  • Cancer Institute Hospital of JFCR

    ACTIVE_NOT_RECRUITING

    Kōtoku, 135-8550, Japan

  • Centre Francois Baclesse

    ACTIVE_NOT_RECRUITING

    Caen, 14076, France

  • Centre Georges François Leclerc

    ACTIVE_NOT_RECRUITING

    Dijon, 21079, France

  • Centre Jean Perrin - CLCC

    ACTIVE_NOT_RECRUITING

    Clermont-Ferrand, 63000, France

  • Centre Leon Berard

    ACTIVE_NOT_RECRUITING

    Lyon, 69008, France

  • Chang Gung Memorial Hospital,Linkou

    ACTIVE_NOT_RECRUITING

    Taoyuan City, 333, Taiwan

  • Chongqing Cancer Hospital

    ACTIVE_NOT_RECRUITING

    Chongqing, 400030, China

  • Churchill Hospital

    ACTIVE_NOT_RECRUITING

    Headington, OX3 7LE, United Kingdom

  • Clinica Universidad de Navarra

    ACTIVE_NOT_RECRUITING

    Pamplona, 31008, Spain

  • Clinica Universidad de Navarra (MAD)

    ACTIVE_NOT_RECRUITING

    Pamplona, 31008, Spain

  • Community Health Network - MD Anderson

    RECRUITING

    Indianapolis, Indiana, 46250, United States

  • Community MD Anderson Cancer Center- East

    ACTIVE_NOT_RECRUITING

    Indianapolis, Indiana, 46219, United States

  • Community MD Anderson Cancer Center- South

    ACTIVE_NOT_RECRUITING

    Indianapolis, Indiana, 46227, United States

  • Cukurova University Medical Faculty

    ACTIVE_NOT_RECRUITING

    Adana, 01790, Turkey (Türkiye)

  • Diagnostic and Therapeutic Centre of Athens "Hygeia" S.A.

    ACTIVE_NOT_RECRUITING

    Marousi, 15123, Greece

  • Duke Cancer Center

    ACTIVE_NOT_RECRUITING

    Durham, North Carolina, 27710, United States

  • Duke Women's Cancer Care- Raleigh

    ACTIVE_NOT_RECRUITING

    Durham, North Carolina, 27607, United States

  • Fakultni nemocnice Brno

    ACTIVE_NOT_RECRUITING

    Brno, 625 00, Czechia

  • Fakultni nemocnice Bulovka

    ACTIVE_NOT_RECRUITING

    Prague, 180 81, Czechia

  • Fakultni nemocnice Hradec Kralove

    ACTIVE_NOT_RECRUITING

    Hradec Králové, 50005, Czechia

  • Fakultni nemocnice v Motole

    ACTIVE_NOT_RECRUITING

    Prague, 150 06, Czechia

  • Florida Cancer Specialists

    RECRUITING

    Lake Mary, Florida, 32746, United States

  • Fondazione IRCCS San Gerardo dei Tintori di Monza

    ACTIVE_NOT_RECRUITING

    Monza, 20900, Italy

  • Fondazione Policlinico Universitario Agostino Gemelli IRCCS

    ACTIVE_NOT_RECRUITING

    Roma, 00168, Italy

  • Froedtert and the Medical College of Wisconsin

    RECRUITING

    Milwaukee, Wisconsin, 53226, United States

  • Fudan University Shanghai Cancer Center

    ACTIVE_NOT_RECRUITING

    Shanghai, 200032, China

  • Fujian Provincial Cancer Hospital

    ACTIVE_NOT_RECRUITING

    Fuzhou, 350015, China

  • Fundação Champalimaud

    ACTIVE_NOT_RECRUITING

    Lisbon, 1400-038, Portugal

  • GenesisCare North Shore (Oncology)

    ACTIVE_NOT_RECRUITING

    St Leonards, 2065, Australia

  • GenesisCare St Andrews Hospital

    ACTIVE_NOT_RECRUITING

    Adelaide, 5000, Australia

  • Gold Coast University Hospital

    ACTIVE_NOT_RECRUITING

    Southport, 4215, Australia

  • Groupe Hospitalier Diaconesses - Hôpital De La Croix Saint Simon

    ACTIVE_NOT_RECRUITING

    Paris, 75571, France

  • Guangxi Medical University Cancer Hospital

    ACTIVE_NOT_RECRUITING

    Nanning, 530021, China

  • Hokkaido University Hospital

    ACTIVE_NOT_RECRUITING

    Sapporo, 060-8648, Japan

  • Holy Name

    RECRUITING

    Teaneck, New Jersey, 07666, United States

  • Hospital Clinic de Barcelona

    ACTIVE_NOT_RECRUITING

    Barcelona, 08036, Spain

  • Hospital Clínico Universitario Valencia

    ACTIVE_NOT_RECRUITING

    Valencia, 46010, Spain

  • Hospital Ernesto Dornelles

    ACTIVE_NOT_RECRUITING

    Porto Alegre, 90.160-093, Brazil

  • Hospital Moinhos de Vento

    ACTIVE_NOT_RECRUITING

    Porto Alegre, 90035-001, Brazil

  • Hospital Professor Doutor Fernando Fonseca, E.P.E.

    ACTIVE_NOT_RECRUITING

    Amadora, 2720-276, Portugal

  • Hospital Universitari Vall d'Hebron

    ACTIVE_NOT_RECRUITING

    Barcelona, 08035, Spain

  • Hospital Universitari i Politecnic La Fe

    ACTIVE_NOT_RECRUITING

    Valencia, 46026, Spain

  • Hospital Universitario 12 de Octubre

    ACTIVE_NOT_RECRUITING

    Madrid, 28041, Spain

  • Hospital Universitario Ciudad de Jaen

    ACTIVE_NOT_RECRUITING

    Jaén, 23007, Spain

  • Hospital Universitario Clinico San Carlos

    ACTIVE_NOT_RECRUITING

    Madrid, 28040, Spain

  • Hospital Universitario La Paz

    ACTIVE_NOT_RECRUITING

    Madrid, 28046, Spain

  • Hospital da Luz

    ACTIVE_NOT_RECRUITING

    Lisbon, 1500-650, Portugal

  • Houston Area Locations- League City

    ACTIVE_NOT_RECRUITING

    League City, Texas, 77573, United States

  • Houston Area Locations- Sugar Land

    ACTIVE_NOT_RECRUITING

    Houston, Texas, 77079, United States

  • Houston Area Locations- West Houston

    ACTIVE_NOT_RECRUITING

    Houston, Texas, 77079, United States

  • Houston Area Locations- Woodlands

    ACTIVE_NOT_RECRUITING

    Conroe, Texas, 77384, United States

  • Houston Methodist Hospital

    RECRUITING

    Houston, Texas, 77030, United States

  • Hubei Cancer Hospital

    ACTIVE_NOT_RECRUITING

    Wuhan, 430079, China

  • Humanitas San Pio X

    ACTIVE_NOT_RECRUITING

    Milan, 20159, Italy

  • Hyogo Cancer Center

    ACTIVE_NOT_RECRUITING

    Akashi-shi, 673-8558, Japan

  • Hôpital Privé du Confluent

    ACTIVE_NOT_RECRUITING

    Nantes, 44277, France

  • I. U. Cerrahpasa Faculty of Med

    ACTIVE_NOT_RECRUITING

    Istanbul, 34153, Turkey (Türkiye)

  • IASO General Clinic

    ACTIVE_NOT_RECRUITING

    Marousi, 15123, Greece

  • ICL Alexis Vautrin

    ACTIVE_NOT_RECRUITING

    Vandœuvre-lès-Nancy, 54500, France

  • ICO Badalona - Hospital Universitari Germans Trias i Pujol

    COMPLETED

    Barcelona, 08916, Spain

  • IEO Istituto Europeo di Oncologia

    ACTIVE_NOT_RECRUITING

    Milan, 20141, Italy

  • IRCCS Centro di Riferimento Oncologico

    ACTIVE_NOT_RECRUITING

    Aviano, 33081, Italy

  • Institut Bergonié

    ACTIVE_NOT_RECRUITING

    Bordeaux, 33076, France

  • Institut Curie

    ACTIVE_NOT_RECRUITING

    Saint-Cloud, 92210, France

  • Institut Paoli Calmettes

    ACTIVE_NOT_RECRUITING

    Marseille, 13273, France

  • Institut du Cancer de Montpellier

    ACTIVE_NOT_RECRUITING

    Montpellier, 34298, France

  • Instituto COI de Pesquisa

    ACTIVE_NOT_RECRUITING

    Rio de Janeiro, 22775-001, Brazil

  • Instituto Português de Oncologia do Porto Francisco Gentil, EPE

    ACTIVE_NOT_RECRUITING

    Porto, 4200-072, Portugal

  • Istanbul University Istanbul Medical Faculty

    ACTIVE_NOT_RECRUITING

    Istanbul, 34093, Turkey (Türkiye)

  • Istituto Clinico Humanitas

    COMPLETED

    Rozzano, 20089, Italy

  • Istituto Nazionale Tumori Fondazione G. Pascale

    ACTIVE_NOT_RECRUITING

    Naples, 80131, Italy

  • Iwate Medical University Hospital

    ACTIVE_NOT_RECRUITING

    Shiwa-gun, 028-3695, Japan

  • Jikei University Hospital

    ACTIVE_NOT_RECRUITING

    Minatoku, 105-8471, Japan

  • Kliniken Essen-Mitte

    ACTIVE_NOT_RECRUITING

    Essen, 45136, Germany

  • Koo Foundation Sun Yat-Sen Cancer Center

    ACTIVE_NOT_RECRUITING

    Taipei, 112, Taiwan

  • Kuopio University Hospital

    ACTIVE_NOT_RECRUITING

    Kuopio, 70210, Finland

  • London Health Sciences Centre (LHSC) - Victoria Hospital

    ACTIVE_NOT_RECRUITING

    London, N6A5W9, Canada

  • Mazowiecki Szpital Wojewodzki w Siedlcach Sp z o o

    ACTIVE_NOT_RECRUITING

    Siedlce, 08-110, Poland

  • McGill University Health Centre/Glen Site / Royal Victoria Hospital

    ACTIVE_NOT_RECRUITING

    Montreal, H4A 3J1, Canada

  • Medical University of South Carolina (MUSC)

    RECRUITING

    Charleston, South Carolina, 29425, United States

  • Medipol University Medical Faculty

    ACTIVE_NOT_RECRUITING

    Istanbul, 34214, Turkey (Türkiye)

  • Mount Sinai Comprehensive Cancer Center

    RECRUITING

    Miami Beach, Florida, 33140, United States

  • NHO Kyushu Cancer Center

    ACTIVE_NOT_RECRUITING

    Fukuoka, 811-1395, Japan

  • NHPP Imbert

    ACTIVE_NOT_RECRUITING

    Bay Shore, New York, 11706, United States

  • NHPP LHH

    ACTIVE_NOT_RECRUITING

    New York, New York, 10065, United States

  • NYU Langone Health

    RECRUITING

    New York, New York, 10016, United States

  • National Cancer Center

    ACTIVE_NOT_RECRUITING

    Goyang-si, 10408, South Korea

  • National Cancer Center Hospital

    ACTIVE_NOT_RECRUITING

    Chūōku, 104-0045, Japan

  • National Cancer Center Hospital East

    ACTIVE_NOT_RECRUITING

    Kashiwa-shi, 277-8577, Japan

  • National Cheng Kung University Hospital

    ACTIVE_NOT_RECRUITING

    Tainan, 70403, Taiwan

  • National Taiwan University Hospital

    ACTIVE_NOT_RECRUITING

    Taipei, 100225, Taiwan

  • Niigata Cancer Center Hospital

    ACTIVE_NOT_RECRUITING

    Niigata, 951-8566, Japan

  • Northampton General Hospital (Ph3)

    ACTIVE_NOT_RECRUITING

    Northampton, NN1 5BD, United Kingdom

  • Northwell Health, LLC PRIME

    RECRUITING

    Lake Success, New York, 11042, United States

  • Ohio State University Wexner Medical Center

    RECRUITING

    Hilliard, Ohio, 43026, United States

  • Okayama University Hospital

    ACTIVE_NOT_RECRUITING

    Okayama, 700-8558, Japan

  • Oklahoma Cancer Specialists and Research Institute

    RECRUITING

    Tulsa, Oklahoma, 12967, United States

  • Oncocentro - Belo Horizonte

    RECRUITING

    Belo Horizonte, 30360680, Brazil

  • Oncology Associates of Oregon, P.C.

    RECRUITING

    Eugene, Oregon, 97401, United States

  • Osaka International Cancer Institute

    ACTIVE_NOT_RECRUITING

    Osaka, 541-8567, Japan

  • Ospedale Mauriziano Umberto I

    ACTIVE_NOT_RECRUITING

    Torino, 10128, Italy

  • Perelman School of Medicine at the University of Pennsylvania

    RECRUITING

    Philadelphia, Pennsylvania, 19104-4238, United States

  • Perlmutter Cancer Center at NYU Langone Hospital- Long Island

    ACTIVE_NOT_RECRUITING

    Mineola, New York, 11501, United States

  • Peter MacCallum Cancer Center

    ACTIVE_NOT_RECRUITING

    Melbourne, 3000, Australia

  • Qilu Hospital of Shandong University

    ACTIVE_NOT_RECRUITING

    Jinan, 250117, China

  • Royal United Hospital

    ACTIVE_NOT_RECRUITING

    Bath, BA1 3NG, United Kingdom

  • Saitama Medical University International Medical Center

    ACTIVE_NOT_RECRUITING

    Hidaka-shi, 350-1298, Japan

  • Samsung Medical Center

    ACTIVE_NOT_RECRUITING

    Seoul, South Korea

  • Sanford Cancer Center Gynecologic Oncology

    RECRUITING

    Sioux Falls, South Dakota, 57104, United States

  • Seoul National University Bundang Hospital

    ACTIVE_NOT_RECRUITING

    Seongnam, 13620, South Korea

  • Seoul National University Hospital

    ACTIVE_NOT_RECRUITING

    Seoul, 03080, South Korea

  • Severance Hospital, Yonsei University Health System - Site 8201

    ACTIVE_NOT_RECRUITING

    Seoul, 03722, South Korea

  • Severance Hospital, Yonsei University Health System - Site 8207

    ACTIVE_NOT_RECRUITING

    Seoul, 03722, South Korea

  • Shandong Cancer Hospital

    ACTIVE_NOT_RECRUITING

    Jinan, 250117, China

  • Shizuoka Cancer Center

    ACTIVE_NOT_RECRUITING

    Nagaizumi-cho, 411-8777, Japan

  • St Luke's Hospital

    ACTIVE_NOT_RECRUITING

    Thessaloniki, 55236, Greece

  • St. Elizabeth Medical Center

    RECRUITING

    Edgewood, Kentucky, 41017, United States

  • Sylvester Cancer Center

    RECRUITING

    Miami, Florida, 33136, United States

  • Sylvester Comprehensive Cancer Center at Deerfield Beach

    ACTIVE_NOT_RECRUITING

    Deerfield Beach, Florida, 33442, United States

  • Sylvester Comprehensive Cancer Center at Lennar

    ACTIVE_NOT_RECRUITING

    Coral Gables, Florida, 33146, United States

  • Sylvester Comprehensive Cancer Center at Plantation

    ACTIVE_NOT_RECRUITING

    Plantation, Florida, 33324, United States

  • Taichung Veterans General Hospital

    ACTIVE_NOT_RECRUITING

    Taichung, 40705, Taiwan

  • Taipei Veterans General Hospital

    ACTIVE_NOT_RECRUITING

    Taipei, 11217, Taiwan

  • Texas Oncology Paris

    RECRUITING

    Fort Worth, Texas, 76104, United States

  • Texas Oncology-Baylor Charles A. Sammons Cancer Center

    ACTIVE_NOT_RECRUITING

    Dallas, Texas, 75246, United States

  • Texas Oncology-Bedford

    ACTIVE_NOT_RECRUITING

    Bedford, Texas, 76022, United States

  • Texas Oncology-Presbyterian Cancer Center Dallas

    ACTIVE_NOT_RECRUITING

    Dallas, Texas, 75231, United States

  • The Catholic University of Korea, Seoul St. Mary's Hospital

    ACTIVE_NOT_RECRUITING

    Seoul, 06591, South Korea

  • The First Affiliated Hospital of Guangzhou Medical University

    ACTIVE_NOT_RECRUITING

    Guangzhou, 510120, China

  • The Ottawa Hospital Cancer Centre

    ACTIVE_NOT_RECRUITING

    Ottawa, K1H 8L6, Canada

  • Tianjin Medical University Cancer Institute & Hospital

    ACTIVE_NOT_RECRUITING

    Tianjin, 453000, China

  • Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

    ACTIVE_NOT_RECRUITING

    Wuhan, 430022, China

  • Universitaetsklinikum Carl Gustav Carus TU Dresden

    ACTIVE_NOT_RECRUITING

    Dresden, 01307, Germany

  • Universitaetsklinikum Hamburg-Eppendorf (Ph3)

    ACTIVE_NOT_RECRUITING

    Hamburg, 20246, Germany

  • Universitaetsklinikum Mannheim

    ACTIVE_NOT_RECRUITING

    Mannheim, 68167, Germany

  • Universitaetsklinikum Ulm

    ACTIVE_NOT_RECRUITING

    Ulm, 89075, Germany

  • University College London Hospitals

    ACTIVE_NOT_RECRUITING

    London, NW1 2PG, United Kingdom

  • University Health Network - Princess Margaret Cancer Centre

    ACTIVE_NOT_RECRUITING

    Toronto, M5G 2M9, Canada

  • University of Oklahoma Health Sciences Center

    RECRUITING

    Oklahoma City, Oklahoma, 73104, United States

  • University of Texas - MD Anderson

    RECRUITING

    Houston, Texas, 77030, United States

  • University of Virginia Comprehensive Cancer Center

    RECRUITING

    Charlottesville, Virginia, 22903, United States

  • University of Washington - Seattle Cancer Care Alliance

    RECRUITING

    Seattle, Washington, 98109, United States

  • Uniwersytecki Szpital Kliniczny W Poznaniu

    ACTIVE_NOT_RECRUITING

    Poznan, 60-569, Poland

  • Uniwersytecki Szpital Kliniczny w Bialymstoku

    ACTIVE_NOT_RECRUITING

    Bialystok, 15-276, Poland

  • Uniwersyteckie Centrum Kliniczne

    ACTIVE_NOT_RECRUITING

    Gdansk, 80-214, Poland

  • Valley Health System

    RECRUITING

    Paramus, New Jersey, 07652, United States

  • Vseobecna fakultni nemocnice v Praze

    ACTIVE_NOT_RECRUITING

    Prague, 128 08, Czechia

  • Washington University School of Medicine Obstetrics and Gynecology

    RECRUITING

    St Louis, Missouri, 63110, United States

  • Yale University School of Medicine

    RECRUITING

    New Haven, Connecticut, 06520, United States

  • Zhejiang Cancer Hospital

    ACTIVE_NOT_RECRUITING

    Hangzhou, 310022, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.